TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has shared an announcement.
Pharmaron Beijing Co., Ltd. announced that its board of directors will convene on October 28, 2025, to review and approve the company’s third-quarter results for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on providing a variety of pharmaceutical services and products.
Average Trading Volume: 15,769,958
Technical Sentiment Signal: Hold
Current Market Cap: HK$60.6B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.